Live bacterial vaccine vectors: an overview
- PMID: 25763014
- PMCID: PMC4323283
- DOI: 10.1590/s1517-83822014000400001
Live bacterial vaccine vectors: an overview
Abstract
Genetically attenuated microorganisms, pathogens, and some commensal bacteria can be engineered to deliver recombinant heterologous antigens to stimulate the host immune system, while still offering good levels of safety. A key feature of these live vectors is their capacity to stimulate mucosal as well as humoral and/or cellular systemic immunity. This enables the use of different forms of vaccination to prevent pathogen colonization of mucosal tissues, the front door for many infectious agents. Furthermore, delivery of DNA vaccines and immune system stimulatory molecules, such as cytokines, can be achieved using these special carriers, whose adjuvant properties and, sometimes, invasive capacities enhance the immune response. More recently, the unique features and versatility of these vectors have also been exploited to develop anti-cancer vaccines, where tumor-associated antigens, cytokines, and DNA or RNA molecules are delivered. Different strategies and genetic tools are constantly being developed, increasing the antigenic potential of agents delivered by these systems, opening fresh perspectives for the deployment of vehicles for new purposes. Here we summarize the main characteristics of the different types of live bacterial vectors and discuss new applications of these delivery systems in the field of vaccinology.
Keywords: DNA vaccine; antigen presentation; bacterial vector; cancer vaccine; vaccine delivery system.
Similar articles
-
Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery.Vaccines (Basel). 2015 Nov 10;3(4):940-72. doi: 10.3390/vaccines3040940. Vaccines (Basel). 2015. PMID: 26569321 Free PMC article. Review.
-
Live bacterial vaccine vector and delivery strategies of heterologous antigen: A review.Immunol Lett. 2018 May;197:70-77. doi: 10.1016/j.imlet.2018.03.006. Epub 2018 Mar 14. Immunol Lett. 2018. PMID: 29550258 Review.
-
Live attenuated bacteria as vectors to deliver plasmid DNA vaccines.Curr Opin Mol Ther. 2003 Feb;5(1):10-9. Curr Opin Mol Ther. 2003. PMID: 12669465 Review.
-
The use of live attenuated bacteria as a delivery system for heterologous antigens.J Drug Target. 2003;11(8-10):471-9. doi: 10.1080/10611860410001670008. J Drug Target. 2003. PMID: 15203915 Review.
-
Recent advances in the development of live, attenuated bacterial vectors.Curr Opin Mol Ther. 2005 Feb;7(1):62-72. Curr Opin Mol Ther. 2005. PMID: 15732531 Review.
Cited by
-
Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities.Vaccines (Basel). 2021 Dec 16;9(12):1490. doi: 10.3390/vaccines9121490. Vaccines (Basel). 2021. PMID: 34960236 Free PMC article. Review.
-
Advances in Oral Subunit Vaccine Design.Vaccines (Basel). 2020 Dec 22;9(1):1. doi: 10.3390/vaccines9010001. Vaccines (Basel). 2020. PMID: 33375151 Free PMC article. Review.
-
Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer.Recent Results Cancer Res. 2021;217:157-195. doi: 10.1007/978-3-030-57362-1_8. Recent Results Cancer Res. 2021. PMID: 33200366 Free PMC article.
-
A SARS-CoV-2 oral vaccine development strategy based on the attenuated Salmonella type III secretion system.J Appl Microbiol. 2022 Oct;133(4):2484-2500. doi: 10.1111/jam.15720. Epub 2022 Jul 31. J Appl Microbiol. 2022. PMID: 35858677 Free PMC article.
-
Recent Advances in Vaccine Technologies.Vet Clin North Am Small Anim Pract. 2018 Mar;48(2):231-241. doi: 10.1016/j.cvsm.2017.10.002. Epub 2017 Dec 6. Vet Clin North Am Small Anim Pract. 2018. PMID: 29217317 Free PMC article. Review.
References
-
- Adachi K, Kawana K, Yokoyama T, Fujii T, Tomio A, Miura S, Tomio K, Kojima S, Oda K, Sewaki T, et al. Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. Vaccine. 2010;28:2810–2817. - PubMed
- Adachi K, Kawana K, Yokoyama T, Fujii T, Tomio A, Miura S, Tomio K, Kojima S, Oda K, Sewaki T et al. (2010) Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. Vaccine 28:2810–2817. - PubMed
-
- Aebischer T, Bumann D, Epple HJ, Metzger W, Schneider T, Cherepnev G, Walduck AK, Kunkel D, Moos V, Loddenkemper C, et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut. 2008;57:1065–1072. - PMC - PubMed
- Aebischer T, Bumann D, Epple HJ, Metzger W, Schneider T, Cherepnev G, Walduck AK, Kunkel D, Moos V, Loddenkemper C et al. (2008) Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut 57:1065–1072. - PMC - PubMed
-
- Alaniz RC, Deatherage BL, Lara JC, Cookson BT. Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo. J Immunol. 2007;179:7692–7701. - PubMed
- Alaniz RC, Deatherage BL, Lara JC, Cookson BT (2007) Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo. J Immunol 179:7692–7701. - PubMed
-
- Ashraf S, Kong W, Wang S, Yang J, Curtiss R. Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine. Vaccine. 2011;29:3990–4002. - PMC - PubMed
- Ashraf S, Kong W, Wang S, Yang J, Curtiss R (2011) Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine. Vaccine 29:3990–4002. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources